Lombardi Comprehensive Cancer Center, Department of Oncology, Georgetown University, Washington, DC 20057, USA.
Clinical and Translational Glycoscience Research Center, Georgetown University Medical Center, Georgetown University, Washington, DC 20057, USA.
Molecules. 2022 Mar 29;27(7):2213. doi: 10.3390/molecules27072213.
Development of high throughput robust methods is a prerequisite for a successful clinical use of LC-MS/MS assays. In earlier studies, we reported that nLC-MS/MS measurement of the O-glycoforms of HPX is an indicator of liver fibrosis. In this study, we show that a microflow LC-MS/MS method using a single column setup for capture of the analytes, desalting, fast gradient elution, and on-line mass spectrometry measurements, is robust, substantially faster, and even more sensitive than our nLC setup. We demonstrate applicability of the workflow on the quantification of the O-HPX glycoforms in unfractionated serum samples of control and liver disease patients. The assay requires microliter volumes of serum samples, and the platform is amenable to one hundred sample injections per day, providing a valuable tool for biomarker validation and screening studies.
高通量稳健方法的开发是 LC-MS/MS 分析成功应用于临床的前提。在早期研究中,我们报道了 HPX 的 O-糖型的 nLC-MS/MS 测量是肝纤维化的一个指标。在这项研究中,我们表明,使用单柱设置进行分析物捕获、脱盐、快速梯度洗脱和在线质谱测量的微流 LC-MS/MS 方法具有稳健性,速度显著提高,灵敏度甚至更高比我们的 nLC 装置。我们证明了该工作流程在定量分析未分级的对照和肝病患者血清样品中的 O-HPX 糖型的适用性。该测定方法需要微升体积的血清样本,该平台每天可进行一百次样品注射,为生物标志物验证和筛选研究提供了有价值的工具。